BioVaxys Technology Corp

BioVaxys’s preclinical study shows its MVP‑S vaccine, combined with anti‑PD‑1 and low‑dose cyclophosphamide, boosts immune response and shrinks ovarian tumors in mice, hinting at a new cancer therapy breakthrough.

BioVaxys Technology Corp, a Canadian biotech firm, is tackling malaria with its VaxMite vaccine while eyeing cancer immunotherapy, but faces steep financial and regulatory challenges.

BioVaxys Technology Corp pioneers malaria vaccines and cancer immunotherapies, positioning itself as a leading Canadian biotech tackling global health challenges.

BioVaxys faces a trading ban amid delayed filings; investors should weigh its malaria vaccine promise against governance gaps and low valuation.

BioVaxys Technology Corp: Vancouver‑based biotech innovating a malaria vaccine and cancer immunotherapy, driving forward global health breakthroughs.

BioVaxys reports promising Phase 1 results for a breast‑cancer vaccine, highlighting its pioneering immunotherapy platform amid financial challenges.

BioVaxys Technology Corp pioneers malaria‑targeting VaxMite vaccine and cancer immunotherapies, aiming to reshape global health with breakthrough biotech solutions.

BioVaxys Technology Corp: Vancouver‑based biotech pioneering malaria vaccine VaxMite, cancer immunotherapies, and global health R&D—track its stock and breakthrough research.

BioVaxys Technology Corp, a Canadian biotech firm, is developing the VaxMite malaria vaccine and exploring cancer immunotherapy, aiming to tackle global health challenges.

BioVaxys Technology Corp. has successfully closed a private placement of unsecured convertible debentures, raising CAD 335,670 in gross proceeds to support the development of its vaccine and immunotherapy pipeline.